top of page

Biopharma Daily Stock Updates - 01/19/21

$XBI $154.22 (+1.64%) 📈


$GRTS (+248.51%) - Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2

$NK (+6.32%) - ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread


$ACRS (+220.24%) - Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

$CYAD (+6.52%) - Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD101 in mCRC at ASCO-GI Symposium

$ACRX (+12.98%) - AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen

$CCCC (+3.18%) - C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies

$COCP (+45.03%) - Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

$DTIL (+29.56%) - Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

$MCRB (+1.96%) - Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium

$MTEM (+6.70%) - Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

$MTCR (+5.67%) - Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

$OMER (+7.75%) - Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA

$PHAT (2.64%) - Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

$RYTM (-0.55%) - Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts

$TCON (+3.93%) - TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

$XBIT (+1.59%) - XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy


$ADMA (+8.74%) - ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook

$MRUS (+6.01%) - Merus N.V. Announces Proposed Public Offering of Common Shares

$NERV (+27.31%) - Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

$EDIT (+5.29%) - Editas Medicine Announces Offering Of Common Stock

$ACRX (+12.98%) - AcelRx Announces Underwritten Public Offering of Common Stock

$ACRS (+220.24%) - Aclaris Announces Proposed Public Offering of Common Stock

$FULC (+6.64%) - Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

$SYRS (+6.03%) - Syros Announces Proposed Offering of Common Stock

$ONCS (-3.04%) - OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

bottom of page